SCHEMBL30749101

SCHEMBL30749101

CNc1nc(CO)nc2c(-c3ccc(N4CCOCC4)cc3OC)csc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LRRK2 Q5S007 2/20 0.44
SUV39H2 Q9H5I1 5/20 0.40
AR P10275 1/20 0.39
INSR P06213 1/20 0.39
ALK Q9UM73 1/20 0.39
TTK P33981 2/20 0.39
MEN1 O00255 2/20 0.39
ALDH1A1 P00352 2/20 0.39
MAPT P10636 2/20 0.39
KMT2A Q03164 2/20 0.39
PKM P14618 1/20 0.39
PTK2 Q05397 1/20 0.38
IRAK4 Q9NWZ3 1/20 0.38
THRB P10828 1/20 0.37
KDM4E B2RXH2 1/20 0.37
HTT P42858 1/20 0.37
CHEK1 O14757 1/20 0.36
TGFBR1 P36897 1/20 0.36
ACVR1 Q04771 1/20 0.36
PIK3CD O00329 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30748957 0.87 LRRK2 (0.41) LRRK2SUV39H2ARINSRALK
SCHEMBL30748740 0.86 LRRK2 (0.50) LRRK2SUV39H2ARINSRALK
SCHEMBL30749032 0.86 PIK3CA (0.41) ALDH1A1MAPTPKMPTK2KDM4E
SCHEMBL30749059 0.83 LRRK2 (0.44) LRRK2SUV39H2INSRALKTTK
SCHEMBL30748842 0.82 LRRK2 (0.47) LRRK2SUV39H2ARINSRALK
SCHEMBL30749011 0.74 PIK3CD (0.36) MEN1ALDH1A1MAPTKMT2APKM
SCHEMBL30748749 0.72 HTR2C (0.43) LRRK2MEN1ALDH1A1MAPTKMT2A
SCHEMBL30749134 0.70 LRRK2 (0.43) LRRK2SUV39H2INSRALKTTK
SCHEMBL30748864 0.69 LRRK2 (0.51) LRRK2SUV39H2INSRALKTTK
SCHEMBL31691352 0.68 PDE4B (0.35) ALDH1A1MAPTPKMKDM4EHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2025-10-02 US disclosed
EP-4565588-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF Suzhou Keen Therapeutics Co., Ltd. (CN) 2025-06-11 EP disclosed
WO-2023241620-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2023-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF VHL, BRCA1, TERT LRRK2 4090/4885SUV39H2 2114/4885AR 57/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.